From the Research
After 10 years of denosumab therapy, a bone density test should be repeated approximately 1-2 years after stopping treatment to assess the risk of rebound-associated bone loss and fractures, as supported by the most recent study 1. Denosumab is a highly effective anti-osteoporosis therapy that produces clinically meaningful increases in bone mineral density (BMD) and reduces fracture risk at key skeletal sites. However, discontinuation of denosumab can lead to a rebound effect, causing rapid loss of BMD and increased risk of multiple vertebral fractures (MVFs) 2, 3, 4, 5. The optimal timing for repeating a bone density test after stopping denosumab therapy is not well established, but the most recent study suggests that it should be done after 1-2 years to assess the risk of rebound-associated bone loss and fractures 1. Some key points to consider when deciding when to repeat a bone density test after denosumab therapy include:
- The risk of rebound-associated bone loss and fractures after stopping denosumab therapy
- The importance of monitoring BMD and bone turnover markers after stopping denosumab therapy
- The potential benefits of transitioning to another anti-osteoporosis therapy after denosumab discontinuation to mitigate the rebound effect
- The need for regular appointments with a healthcare provider to discuss the ongoing treatment plan and any potential adjustments based on DEXA results and overall health status. It's also important to note that the rebound effect after stopping denosumab therapy can be associated with hypercalcemia, parathyroid hyperplasia, and severe bone mineral density loss, as reported in a case study 5. In summary, repeating a bone density test approximately 1-2 years after stopping denosumab therapy is recommended to assess the risk of rebound-associated bone loss and fractures, and to guide further treatment decisions 1.